PH12022553276A1 - Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasms - Google Patents
Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasmsInfo
- Publication number
- PH12022553276A1 PH12022553276A1 PH1/2022/553276A PH12022553276A PH12022553276A1 PH 12022553276 A1 PH12022553276 A1 PH 12022553276A1 PH 12022553276 A PH12022553276 A PH 12022553276A PH 12022553276 A1 PH12022553276 A1 PH 12022553276A1
- Authority
- PH
- Philippines
- Prior art keywords
- combination
- ruxolitinib
- treatment
- incb057643
- myeloproliferative neoplasms
- Prior art date
Links
- VZSAMEOETVNDQH-UHFFFAOYSA-N CC1(OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C Chemical compound CC1(OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C VZSAMEOETVNDQH-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 title abstract 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 title abstract 2
- 229960000215 ruxolitinib Drugs 0.000 title abstract 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 title abstract 2
- 229940088617 BET protein inhibitor Drugs 0.000 abstract 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 abstract 1
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 abstract 1
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 abstract 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063034214P | 2020-06-03 | 2020-06-03 | |
| PCT/US2020/050753 WO2021247064A1 (en) | 2020-06-03 | 2020-09-14 | Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022553276A1 true PH12022553276A1 (en) | 2024-02-19 |
Family
ID=72659928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/553276A PH12022553276A1 (en) | 2020-06-03 | 2020-09-14 | Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasms |
Country Status (23)
| Country | Link |
|---|---|
| EP (2) | EP4161528B1 (https=) |
| JP (2) | JP7669396B2 (https=) |
| KR (1) | KR20230031242A (https=) |
| CN (1) | CN115835868A (https=) |
| AU (1) | AU2020451061A1 (https=) |
| CA (1) | CA3184633A1 (https=) |
| CL (1) | CL2022003409A1 (https=) |
| DK (1) | DK4161528T3 (https=) |
| ES (1) | ES3058891T3 (https=) |
| FI (1) | FI4161528T3 (https=) |
| HR (1) | HRP20251457T1 (https=) |
| IL (1) | IL298200A (https=) |
| LT (1) | LT4161528T (https=) |
| MA (1) | MA59868B1 (https=) |
| MD (1) | MD4161528T2 (https=) |
| MX (1) | MX2022015220A (https=) |
| PH (1) | PH12022553276A1 (https=) |
| PL (1) | PL4161528T3 (https=) |
| PT (1) | PT4161528T (https=) |
| RS (1) | RS67440B1 (https=) |
| SI (1) | SI4161528T1 (https=) |
| SM (1) | SMT202600021T1 (https=) |
| WO (1) | WO2021247064A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023009858A (es) * | 2021-02-25 | 2023-09-12 | Impact Biomedicines Inc | Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis. |
| WO2024039883A2 (en) * | 2022-08-19 | 2024-02-22 | Translational Drug Development Llc | Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms |
| AU2024306742A1 (en) * | 2023-06-28 | 2025-12-04 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of mpn |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| KR20150036210A (ko) | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| PL3134403T3 (pl) * | 2014-04-23 | 2020-07-13 | Incyte Corporation | 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET |
| CA3028689A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
-
2020
- 2020-09-14 PT PT207812025T patent/PT4161528T/pt unknown
- 2020-09-14 AU AU2020451061A patent/AU2020451061A1/en active Pending
- 2020-09-14 SI SI202030684T patent/SI4161528T1/sl unknown
- 2020-09-14 DK DK20781202.5T patent/DK4161528T3/da active
- 2020-09-14 LT LTEPPCT/US2020/050753T patent/LT4161528T/lt unknown
- 2020-09-14 KR KR1020227046429A patent/KR20230031242A/ko active Pending
- 2020-09-14 EP EP20781202.5A patent/EP4161528B1/en active Active
- 2020-09-14 FI FIEP20781202.5T patent/FI4161528T3/fi active
- 2020-09-14 CA CA3184633A patent/CA3184633A1/en active Pending
- 2020-09-14 JP JP2022574520A patent/JP7669396B2/ja active Active
- 2020-09-14 HR HRP20251457TT patent/HRP20251457T1/hr unknown
- 2020-09-14 EP EP25209713.4A patent/EP4691563A3/en active Pending
- 2020-09-14 IL IL298200A patent/IL298200A/en unknown
- 2020-09-14 MD MDE20230400T patent/MD4161528T2/ro unknown
- 2020-09-14 WO PCT/US2020/050753 patent/WO2021247064A1/en not_active Ceased
- 2020-09-14 MX MX2022015220A patent/MX2022015220A/es unknown
- 2020-09-14 ES ES20781202T patent/ES3058891T3/es active Active
- 2020-09-14 PH PH1/2022/553276A patent/PH12022553276A1/en unknown
- 2020-09-14 SM SM20260021T patent/SMT202600021T1/it unknown
- 2020-09-14 MA MA59868A patent/MA59868B1/fr unknown
- 2020-09-14 RS RS20251189A patent/RS67440B1/sr unknown
- 2020-09-14 CN CN202080101656.6A patent/CN115835868A/zh active Pending
- 2020-09-14 PL PL20781202.5T patent/PL4161528T3/pl unknown
-
2022
- 2022-12-01 CL CL2022003409A patent/CL2022003409A1/es unknown
-
2025
- 2025-04-16 JP JP2025067272A patent/JP2025111539A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL298200A (en) | 2023-01-01 |
| LT4161528T (lt) | 2026-02-10 |
| SI4161528T1 (sl) | 2026-01-30 |
| EP4691563A2 (en) | 2026-02-11 |
| JP2023529365A (ja) | 2023-07-10 |
| EP4161528A1 (en) | 2023-04-12 |
| JP7669396B2 (ja) | 2025-04-28 |
| CN115835868A (zh) | 2023-03-21 |
| FI4161528T3 (fi) | 2025-12-12 |
| MX2022015220A (es) | 2023-03-08 |
| WO2021247064A1 (en) | 2021-12-09 |
| RS67440B1 (sr) | 2025-12-31 |
| DK4161528T3 (da) | 2025-11-24 |
| HRP20251457T1 (hr) | 2026-01-02 |
| PT4161528T (pt) | 2026-01-23 |
| SMT202600021T1 (it) | 2026-03-09 |
| CL2022003409A1 (es) | 2023-05-26 |
| ES3058891T3 (en) | 2026-03-13 |
| AU2020451061A1 (en) | 2022-12-15 |
| CA3184633A1 (en) | 2021-12-09 |
| EP4691563A3 (en) | 2026-04-01 |
| KR20230031242A (ko) | 2023-03-07 |
| JP2025111539A (ja) | 2025-07-30 |
| MD4161528T2 (ro) | 2026-03-31 |
| PL4161528T3 (pl) | 2026-03-16 |
| MA59868B1 (fr) | 2025-11-28 |
| EP4161528B1 (en) | 2025-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022553276A1 (en) | Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasms | |
| BR0308407A (pt) | Compostos de quinazolina úteis em terapia | |
| MX2020010675A (es) | Derivados de pirazolo-triazina y/o pirazolo-pirimidina como inhibidor selectivo de cinasa dependiente de ciclina. | |
| ATE327756T1 (de) | Verwendung von cgmp-phosphodiesterase hemmer zur behandlung von impotenz | |
| BR0313461A (pt) | Novas imidazopiridinas e respectivo uso das mesmas | |
| ATE546143T1 (de) | Mittel zur behandlung von glaukom mit einem rho- kinase-hemmer und prostaglandinen | |
| DE69830503D1 (de) | Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit | |
| MY141144A (en) | 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases | |
| ATE335490T1 (de) | Staurosporin-derivate als hemmer der flt3- rezeptor-tyrosinkinase-wirkung | |
| TW200503719A (en) | Pyridino [1,2-a] pyrimidin-4-one compounds as anticancer agents | |
| IL151695A0 (en) | Substituted beta-carbolines with ikb-kinase inhibiting activity | |
| NZ544244A (en) | Dual NK1/NK3 antagonists for treating schizophrenia | |
| PE20141023A1 (es) | Derivados de (1,2,4) triazolo [4,3-a] quinoxalina como inhibidores de fosfodiesterasas | |
| NZ592641A (en) | 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine, its salts, and uses in medical treatment | |
| BG105445A (en) | Phermaceutical agents for the treatment of parkinson's disease, adhd and microadenomas | |
| TR200402342T4 (tr) | 2-Pirindinil-6,7,8,9- Tetrahidropyrimido[1,2-A] Pirimidin-4-On ve 7-Pirindinil-1,3-Dihydoimidazo[1,2-A]Pirimidin-5(1H) on Türevleri | |
| MX2024015077A (es) | Benzopirimidina-4(3h)-onas como inhibidores de pi3k | |
| NZ589108A (en) | Imidazo [2,1-b] quinazolin-2-one derivatives and their use as platelet anti-aggregative agents | |
| DE60019937D1 (de) | Kombination therapie mit pentafluorobenzenesulfonamid und platin-derivate | |
| ATE388151T1 (de) | Trizyklische purin derivate und deren analoga als inhibitoren des cytokinsignals | |
| MX2023014433A (es) | Compuesto de pirazolo[1,5-a] pirimidina para el tratamiento de trastornos dermicos. | |
| JO2550B1 (en) | Pyrido [3,2-d] derivatives pyrimidine, its preparation, use therapeutically | |
| GR3000266T3 (en) | Pyrido û1,2-a¨pyrimidine derivatives | |
| ATE297926T1 (de) | Hexahydropyrazino(1'2':1,6)-pyrido(3,4-b)indole 1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen | |
| AR057061A1 (es) | Espiro-bencimidazoles farmaceuticamente activos y su uso en la fabricacion de medicamentos |